Breaking News

Rupatadine responder analysis in chronic urticaria

Rupatadine responder analysis in chronic urticaria


Pooled data from two 4-week randomized, double-blind, placebo-controlled, multicenter trials in 538 chronic urticaria (CU) patients evaluated the efficacy of the antihistamine rupatadine. Variables analyzed included the Mean Pruritus Score (MPS), Mean Number of Wheals (MNW) and Urticaria Activity Score (UAS). Responder rates were expressed as the percentage of patients with decreases in symptom scores of 50% or more and 75% or more. Rupatadine 10 mg (R10) and 20 mg (R20) both significantly decreased MPS, MNW and UAS scores versus placebo. The percentage of patients showing a ≥ 50% reduction in MPS was 48.9, 68.31 and 76% in the placebo, R10 and R20 groups, respectively (P < 0.001 R10 vs. placebo ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list